AASLD 2011: Milk Thistle Extract Did Not Improve Liver Inflammation or Quality of Life for Hepatitis C Patients
- Details
- Category: Alternative & Complementary Therapy
- Published on Tuesday, 06 December 2011 00:00
- Written by Liz Highleyman
Oral silymarin, an extract from the milk thistle plant, was well-tolerated but did not reduce alanine aminotransferase (ALT) or HCV RNA levels or improve quality of life for hepatitis C patients who did not respond to interferon, researchers reported at the 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD 2011) last month in San Francisco. 
AASLD 2011: Daclatasvir with Pegylated Interferon/ Ribavirin Produces High Rates of HCV Suppression
- Details
- Category: HCV Treatment
- Published on Tuesday, 06 December 2011 00:00
- Written by Liz Highleyman
Most treatment-naive chronic hepatitis C patients who added the experimental HCV NS5A inhibitor daclatasvir (BMS-790052) to pegylated interferon/ribavirin achieved undetectable viral load at 12 and 24 weeks, according to data presented at the at the 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD 2011) last month in San Francisco.
AASLD 2011: Upping Entecavir Dose Does Not Improve Hepatitis B Treatment Response
- Details
- Category: HBV Treatment
- Published on Tuesday, 29 November 2011 00:00
- Written by Liz Highleyman
Doubling the usual dose of entecavir (Baraclude) did not increase its effectiveness for treating chronic hepatitis B, according to a study presented at the 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD 2011) this month in San Francisco.
AASLD 2011: All-Oral Combination of BI 201335, BI 207127 and Ribavirin Shows Good Efficacy at 12 Weeks
- Details
- Category: HCV Treatment
- Published on Thursday, 01 December 2011 00:00
- Written by Liz Highleyman
An interferon-free triple regimen containing the hepatitis C virus (HCV) protease inhibitor BI 201335, the HCV polymerase inhibitor BI 207127, and ribavirin for 12 weeks suppressed viral load in three-quarters of previously untreated genotype 1 patients, according to findings from the SOUND-C trials presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) in San Francisco.
AASLD 2011: Predictors of Response to Boceprevir plus Pegylated Interferon/Ribavirin
- Details
- Category: HCV Treatment
- Published on Tuesday, 29 November 2011 00:00
- Written by Liz Highleyman
Low baseline viral load, hepatitis C virus (HCV) subtype 1b, and absent or mild liver damage predicted sustained response to treatment with boceprevir (Victrelis) plus pegylated interferon/ribavirin, researchers report at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this month in San Francisco.
More Articles...
- AASLD 2011: Upping Ribavirin Dose Does Not Increase Interferon Effectiveness in HIV/HCV Coinfected Patients
- AASLD 2011: HCV Screening of 1945-1965 Birth Cohort Appears Cost-Effective
- AASLD 2011: Good Response to Entecavir Reduces Risk of Hepatitis B Liver Disease Progression
- AASLD 2011: High Sustained Response Rates with PSI-7977 Plus Pegylated Interferon/Ribavirin
Web Design and Development by